Alvotech Stock Jumps on Barclays Upgrade to Overweight Ahead of FDA Decisions

Shares of Alvotech (NASDAQ:ALVO) surged on Wednesday after Barclays upgraded the biotechnology company to Overweight, citing increased confidence in its ability to secure U.S. regulatory approval for three key biosimilar drug candidates later this year. The stock closed up 7.3% following the analyst note.

Barclays Lifts Rating

Barclays analyst Glen Santangelo raised the firm's rating on Alvotech to Overweight from a previous Underweight and doubled the price target to $8.00 per share from $4.00. The upgrade reflects a more positive outlook on the company's regulatory and manufacturing standing ahead of critical deadlines.

The firm's valuation model for the new price target assumes the successful U.S. approval of the three biologics. Barclays projects that this, combined with previously referenced milestone revenue, could drive adjusted EBITDA to a range of $270-290 million next year, justifying a 15-16x multiple.

FDA Decision Looms

The upgrade is primarily driven by an anticipated U.S. Food and Drug Administration (FDA) decision on December 4, 2026. Alvotech resubmitted its Biologics License Applications (BLAs) in June for its proposed biosimilars to several major drugs:

Ad

• Simponi and Simponi Aria (AVT05)
• Eylea (AVT06)
• Prolia and Xgeva (AVT03)

The applications were refiled after the company previously received Complete Response Letters (CRLs) from the agency. The FDA has confirmed a standard six-month review process, making the December goal date a critical catalyst for the company.

Manufacturing and Financial Outlook

A key factor underpinning Barclays' optimism is the recent resolution of manufacturing concerns. The FDA completed a surveillance inspection of Alvotech’s Reykjavik facility in May and formally closed it in July with a 'Voluntary Action Indicated' classification. The company has stated the facility is back to full-scale manufacturing capacity.

Alvotech reaffirmed its fiscal 2026 revenue target of $650-700 million during its recent second-quarter report. The successful resolution of the facility inspection and potential approvals are seen as crucial steps toward achieving this financial guidance.